

Final Report on Recruitment (DPMS)

Publishable Summary

After finalizing the numbers for study recruitment during the last quarter, a focus was made during Q3 to ensure that all data collected at each site was available in the database. With this done, we can confirm that DPMS included 844 patients, and performed 862 scans in total.

The key aspect was to keep the maximum number of patients in the study for the primary endpoint, at week 12, in spite of the difficult Covid-19 period from early 2020 onwards. With a great effort of all sites, despite their own local and national restrictions, it has been possible to keep the dropout rate below 5% between baseline and week 12 (the primary end-point).

The third quarter of 2021 was dedicated to data cleaning, with many exchanges with sites. This has allowed the DPMS team to make a great step forward towards a clean dataset.

At the end of September, the number of queries for data correction had dropped from several thousands to less than 50, and the remainder is expected to be finalized in the next weeks.

Additionally, 2629 patient diaries have been collected throughout the study, making it possible for the health economics analysis to proceed (currently ongoing).

The paper describing enrolment strategies and baseline features of the DPMS participants is currently under review by Alzheimer's & Dementia. Preliminary analyses of DPMS primary endpoint have been presented at the General Assembly and a first version of the manuscript has been drafted.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

